Effects of naloxegol on transit recovery in patients undergoing cardiac surgery: A randomized, double-blind, placebo-controlled trial

被引:0
|
作者
Laghlam, Driss [1 ]
Gibert, Hadrien [2 ]
Merzoug, Messaouda [3 ]
Leclerc, Didier [2 ]
Coroyer, Lucas [1 ]
Estagnasie, Philippe [1 ]
Squara, Pierre [1 ]
Nguyen, Lee S. [1 ]
Geri, Guillaume [1 ]
机构
[1] CMC Ambroise Pare Hartmann, Dept Cardiol & Crit Care, 48 Ter Blvd Victor Hugo, F-92200 Neuilly Sur Seine, France
[2] CMC Ambroise Pare Hartmann, Dept Cardiovasc Anesthesiol, 48 Ter Blvd Victor Hugo, F-92200 Neuilly Sur Seine, France
[3] CMC Ambroise Pare Hartmann, Dept Clin Res, 48 Ter Blvd Victor Hugo, F-92200 Neuilly Sur Seine, France
关键词
Cardiac surgery; Cardiopulmonary bypass; Gastrointestinal complications; Naloxegol; Pain; Paralytic ileus; OPIOID-INDUCED CONSTIPATION; GASTROINTESTINAL COMPLICATIONS; MORBIDITY; EFFICACY;
D O I
10.1016/j.accpm.2025.101498
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Paralytic ileus is a major surrounding after cardiac surgery and worsens patients' prognosis. Methods: We conducted a single-centre, randomized, double-blind, placebo-controlled phase 3 study. We enrolled patients over 18 years old who underwent non-urgent cardiac surgery. Eligible patients were randomly allocated to Naloxegol or matching placebo in an equal ratio. The participants were randomly assigned to one of the following groups: (1) Naloxegol 12,5 mg 2 h before index surgery, and then Naloxegol 25 mg once daily, or (2) matching placebo. Naloxegol or placebo was administered for up to 5 days and permanently stopped if the patient had transit recovery. The primary endpoint was the time of postoperative gastrointestinal transit recovery after the index cardiac surgery, defined as the time in hours between the anaesthetic induction and the emission of the first significant stool. Results: Between October 14, 2020, and January 28, 2022, 299 participants were included in modified intention-to-treat efficacy analyses (151 in the Naloxegol group and 148 in placebo). The mean age was 62 f 10.1 years old, 81.6% were male, 53.8% had hypertension, 20.7% had diabetes mellitus, and the median body mass index was 25.9 (IQR 23.7-29.4) kg/m2. Time-to-transit recovery did not differ between Naloxegol group and placebo (76.0, [IQR 69.3-93.5] vs. 78.3, [IQR 70.0-95.8] h, p value = 0.40). We did not observe any difference in the prespecified secondary efficacy between both groups. Pain levels and a number of serious adverse events were not different in both groups. Conclusions: Naloxegol was not found to be effective in improving the transit time recovery after elective cardiac surgery. The trial was registered on ClinicalTrials.gov (NCT04433390) on June 16th, 2020. (c) 2025 Societe Franc,aise d'Anesthesie et de Reanimation (SFAR). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial
    Sadrifar, Sina
    Abbasi-Dokht, Tannaz
    Forouzandeh, Sarvenaz
    Malek, Farhad
    Yousefi, Bahman
    Farrokhi, Amir Salek
    Karami, Jafar
    Baharlou, Rasoul
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2023, 19 (01):
  • [32] Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial
    Moradi, Sajjad
    Bagheri, Reza
    Amirian, Parsa
    Zarpoosh, Mahsa
    Cheraghloo, Neda
    Wong, Alexei
    Zobeiri, Mehdi
    Entezari, Mohammad Hassan
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2024, 24 (01)
  • [33] Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial
    Bergasa, Nora V.
    McGee, Monnie
    Ginsburg, Iona H.
    Engler, Danielle
    HEPATOLOGY, 2006, 44 (05) : 1317 - 1323
  • [34] Randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis
    Coyle, K.
    Pokrovnichka, A.
    French, K.
    Joe, G.
    Shrader, J.
    Swan, L.
    Cabalar, I.
    Harris-Love, M.
    Plotz, P.
    Miller, F.
    Gourley, M.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S923 - S924
  • [35] Vasculoprotective effects of dietary flavanols in hemodialysis patients: a double-blind, randomized, placebo-controlled trial
    Rammos, C.
    Hendgen-Cotta, U. B.
    Heiss, C.
    Hetzel, G. R.
    Kleophas, W.
    Dellanna, F.
    Ottaviani, J.
    Schroeter, H.
    Kelm, M.
    Rassaf, T.
    EUROPEAN HEART JOURNAL, 2015, 36 : 355 - 356
  • [36] Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial
    Kruiper, Caitlyn
    Sommer, Iris E. C.
    Koster, Michiel
    Bakker, P. Roberto
    Durston, Sarah
    Oranje, Bob
    SCHIZOPHRENIA RESEARCH, 2023, 255 : 148 - 154
  • [37] A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Receiving Codeine or Placebo
    Halawi, Houssam
    Vijayvargiya, Priya
    Busciglio, Irene
    Oduyebo, Ibironke
    Khemani, Disha
    Ryks, Michael
    Rhoten, Deborah
    Burton, Duane
    Szarka, Lawrence A.
    Acosta, Andres
    Camilleri, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S230 - S230
  • [38] Prevention of MACE with modified glucose-insulin-potassium in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled trial
    Zhao, K.
    Li, J.
    Zheng, Q. J.
    Chen, W. S.
    Cui, Q.
    Yu, S. Q.
    Yi, D. H.
    Gao, F.
    EUROPEAN HEART JOURNAL, 2014, 35 : 525 - 525
  • [39] A randomized, double-blind, placebo-controlled pilot trial of triiodothyronine in neonatal heart surgery
    Mackie, AS
    Booth, KL
    Newburger, JW
    Gauvreau, K
    Huang, SA
    Laussen, PC
    DiNardo, JA
    del Nido, PJ
    Mayer, JE
    Jonas, RA
    McGrath, E
    Elder, J
    Roth, SJ
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (03): : 810 - 816
  • [40] A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL OF PERIOPERATIVE INTRAVENOUS ACETAMINOPHEN IN CARDIAC SURGERY
    Choi, W. P.
    Jelacic, S.
    Cain, K. C.
    Richebe, P.
    ANESTHESIA AND ANALGESIA, 2014, 118 : S59 - S59